February 13, 2024

Understanding Palbociclib (Ibrance) in Advanced Breast Cancer Treatment

Palbociclib (Ibrance) is a CDK4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC).
Oncology Protocols Pairing
This website uses cookies to improve your experience. By using this website you agree to our Cookie Policy.
Read more